secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0001104659-24-025617
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance prices $211M common stock offering at $9.15/share
---------------------------------------------------------

- Issues 23,014,000 shares at $9.15; gross proceeds ~$211M, net ~$197.1M.
- Net proceeds to support AMTAGVI commercial launch, NSCLC study IOV-LUN-202, melanoma trial TILVANCE-301.
- Underwriters include Jefferies, Barclays, Goldman Sachs; closing expected Feb 22, 2024.
- Executive officers and directors subject to 60-day lock-up on stock sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924025617/0001104659-24-025617-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924025617/tm246746d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-025617

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer